ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Lyell Immunopharma, Inc. Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.	United States of America	LYEL
Lyra Therapeutics, Inc. Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).	United States of America	LYRA
Lytix Biopharma AS Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.	Norway	LYTIX
MaaT Pharma Developing gut microbiome therapies to improve survival for cancer patients.	France	MAAT
Mabion S.A. Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.	Poland	MAB
MACROGENICS INC Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.	United States of America	MGNX
MADRIGAL PHARMACEUTICALS, INC. Develops and delivers the first FDA-approved treatment for the liver disease MASH.	United States of America	MDGL
Magle Chemoswed Holding AB A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.	Sweden	MAGLE
Mainz BioMed N.V. Develops at-home diagnostic tests for the early detection of life-threatening cancers.	Germany	MYNZ
MAINZ BIOMED N.V. Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.	United States of America	MYNZ